POSB314 Method of Predicting Serotype Specific Effectiveness Against Invasive Pneumococcal Disease for Pneumococcal Conjugate Vaccines in Infant Population

Autor: Ryman, J, Yee, KL, Weaver, J, Hu, T, Sachs, J

Publikováno v: In Value in Health January 2022 25(1) Supplement:S205-S205

Treatment with Cyclophosphamide in Elderly-Onset Nephrotic Syndrome

Autor: Mak, Siu-ka SM, Lo, Kin-yee KL, Wong, Calvin Y. CYW, Tong, Gensy M.W. GMWT, Wong, Ping-nam PW, Wong, Andrew K.M. AKMW

Publikováno v: Nephron Clinical Practice; January 2005, Vol. 101 Issue: 1 p25-32, 8p

Dealing With Variable Drug Exposure Due to Variable Hepatic Metabolism: A Proof-of-Concept Application of Liquid Biopsy in Renal Impairment.

Autor: Rostami-Hodjegan A; Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK.; Certara, Princeton, New Jersey, USA., Al-Majdoub ZM; Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK., von Grabowiecki Y; Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK., Yee KL; Merck & Co., Inc., Rahway, New Jersey, USA., Sahoo S; Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK., Breitwieser W; Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK., Galetin A; Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK., Gibson C; Merck & Co., Inc., Rahway, New Jersey, USA., Achour B; Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, The University of Rhode Island, Kingston, Rhode Island, USA.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Sep; Vol. 116 (3), pp. 814-823. Date of Electronic Publication: 2024 May 13.

Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen.

Autor: Ryman J; Quantitative Pharmacology and Pharmacometrics, Merck & Co Inc, Rahway, NJ, USA., Sachs JR; Quantitative Pharmacology and Pharmacometrics, Merck & Co Inc, Rahway, NJ, USA., Banniettis N; Clinical Research, Merck & Co., Inc, Rahway, NJ, USA., Weiss T; Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, USA., Ahsman M; Quantitative Pharmacology and Pharmacometrics, Merck & Co Inc, Rahway, NJ, USA., Yee KL; Quantitative Pharmacology and Pharmacometrics, Merck & Co Inc, Rahway, NJ, USA., Weaver J; Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, USA.

Publikováno v: Expert review of vaccines [Expert Rev Vaccines] 2024 Jan-Dec; Vol. 23 (1), pp. 467-473. Date of Electronic Publication: 2024 Apr 09.

Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.

Autor: Melvin AJ; Department of Pediatrics, Division of Pediatric Infectious Disease, University of Washington and Seattle Children's Research Institute, Seattle, WA., Yee KL; Merck & Co., Inc., Rahway, NJ., Gray KP; Harvard T.H. Chan School of Public Health, Boston, MA.; Frontier Science Technology and Research Foundation, Brookline, MA., Yedla M; Frontier Science Technology and Research Foundation, Brookline, MA., Wan H; Merck & Co., Inc., Rahway, NJ., Tobin NH; Department of Pediatrics, Division of Pediatric Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA., Teppler H; Merck & Co., Inc., Rahway, NJ., Campbell H; Merck & Co., Inc., Rahway, NJ., McCarthy K; FHI 360, Durham, NC., Scheckter R; FHI 360, Durham, NC., Aurpibul L; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand., Ounchanum P; Chiangrai Prachanukroh Hospital PHPT, Chiang Rai, Thailand., Rungmaitree S; Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand., Cassim H; PHRU, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa., McFarland E; Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Denver, CO., Flynn P; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN., Cooper E; Boston Medical Center, Boston University School of Medicine, Boston, MA., Krotje C; Frontier Science, Amherst, NY., Townley E; DAIDS/NIAID/NIH, Rockville, MD., Moye J; NICHD/NIH, Bethesda, MD; and., Best BM; Skaggs School of Pharmacy and Pharmaceutical Sciences and Pediatrics Department, School of Medicine-Rady Children's Hospital San Diego, University of California San Diego, San Diego, CA.

Publikováno v: Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2023 Feb 01; Vol. 92 (2), pp. 153-161.